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Introduction
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder among the elderly. Until now, no effective medical treatment or preventative approach exists. Two of the typical neuropathological hallmarks of AD are neuritic plaques that formed by the aggregation of β-amyloid peptides (Aβ), and neurofibrillary tangles, composed of hyperphosphorylated tau (1; 2) . Since overt accumulation of Aβ induces tau phosphorylation, Aβ is considered to be the causative factor for neurodegeneration (1) (2) (3) . Aβ is produced by sequential proteolytic cleavage of amyloid beta precursor protein (APP) via beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and gamma secretase (γ-secretase) complex in the amyloidogenic pathway. BACE1 initiates β-amyloidogenic processing of APP, which makes BACE1 a major drug target for AD therapies. Currently, several promising BACE1 inhibitors are undergoing phase 2/3 clinical trials (4) (5) (6) .
Although Bace1 knockout mice are viable and fertile, they have subtle neurological abnormalities like impaired memory, reduced dendritic spine density in the hippocampus, and decreased myelination (7) (8) (9) .
At least some of these abnormalities may be developmental deficits. However, the inhibition of BACE1 in adult mice has been reported to decrease post-synaptic spine density (10) , but whether BACE1 inhibitor treatment would causes similar deficits in humans remains unknown. Furthermore, it is also unclear which substrates are responsible for BACE1-inhibition-induced alterations of post-synaptic spines. Since synaptic loss correlates with cognitive impairments as reported in AD patients and AD mouse models (11; 12) , it is necessary to identify the molecular mechanism by which BACE1 inhibition impairs synaptic function .
Seizure protein 6 (Sez6) is a type I trans-membrane protein expressed in neurons. The full length Sez6 (flSez6) is nearly exclusively cleaved by BACE1 generating a secreted soluble ectodomain (sSez6) and a transmembrane C-terminal fragment (Sez6-CTF) (13) (14) (15) . Later this Sez6-CTF will be further cleaved by γ-secretase, generating intracellular domain (Sez6-ICD) (16) . Sez6 mainly locates in the somatodendritic compartment, specifically in the dendritic plasma membrane, synaptosomes and post-synaptic density fractions (13; 17-19) , as well as in recycling endosomes (T. Palumaa et al., 2012, SOBR Symposium, abstract) suggesting that Sez6 may modulate synaptic function. Similar to BACE1 inhibitor treated mice (10) , Sez6 -/-mice have reduced dendritic spine density and spatial memory deficit (17) . Constitutive Sez6
-/-mice also show poor motor coordination (17) , which is observed in BACE1 inhibitor treated mice (20) .
Recent whole-exome sequencing studies identified Sez6 variants in human patients with severe intellectual disability and childhood onset schizophrenia (21; 22) .
To shed light on the mechanism of BACE1-inhibition-induced synaptic alteration, we used chronic in vivo two-photon imaging to investigate the structural post-synaptic plasticity in constitutive and conditional Sez6 knockout mice upon BACE1 inhibition. In addition, ex vivo electrophysiological recordings were used to study the functional synaptic plasticity in BACE1 inhibitor treated Sez6 knockout mice. Our data indicate that Sez6 is important for maintaining normal dendritic spine dynamics and synaptic functions.
Moreover, Sez6 is critically involved in BACE1-inhibition-induced synaptic deficits in adult mice. Our findings imply that soluble Sez6 might be used as a biomarker in BACE1 inhibitor treated AD patients to adjust inhibitor dosage to achieve optimal clinical efficacy and safety.
Methods and Materials

Mice and Drug Administration
C57BL/6J mice were purchased from Charles River Laboratories (Sulzfeld, Germany (27) .
Supplementary Methods
For a detailed description of protein extraction, immunoblotting, cranial window implantation, in vivo twophoton imaging, immunohistochemistry experiments and electrophysiological recordings see supplementary materials.
Results
Brain Levels of BACE1 Cleavage Products Decrease after NB-360 Treatment
In this study, we used the BACE1 inhibitor NB-360 developed by Novartis Pharma AG (Basel, Switzerland). NB-360 is a small molecule compound (molecular structure is shown in Figure S1A ), which efficiently crosses the blood-brain-barrier (26) . To minimize the stress caused by repeated drug administration to experimental animals, the inhibitor was added to the mouse diet. Mice consumed 4.6±0.1 g food pellets per day (N = 44). Body weight loss and health impairments were not observed during and after prolonged treatment (data not shown). Interestingly, most of the NB-360 treated mice developed hair depigmentation ( Figure S1B ), because the BACE1 inhibitor NB360 also inhibits BACE2, which is involved in melanogenesis (10; 26; 28; 29) .
To confirm the efficiency of NB-360 inhibition, we analyzed the protein levels of the BACE1 substrates, Respectively, the BACE1 cleavage products sSez6, sAPPβ and β-CTF were significantly decreased in NB-360 treated WT and Bace1 -/-mice confirming the reduced enzymatic activity of BACE1. In summary, these results confirm that NB-360 is a potent inhibitor of BACE1. 
BACE1 Inhibition does not
BACE1 Inhibition does not Affect Dendritic Spine Plasticity in Pyramidal Neurons
Lacking Sez6
To further investigate the impact of Sez6 deletion in mature neurons, we crossed Sez6 :SlickV). We have shown previously that tamoxifen treatment does not affect dendritic spine density (27) . A small but significantly decrease in dendritic spine density of cortical layer V pyramidal cells was observed in Sez6 cKO neurons ( Figure 3A -B). To assess whether this slight reduction in spine density also occurred in other brain regions, we analyzed apical and basal dendrites of hippocampal CA1 eYFP/CreER T2 positive neurons by confocal microscopy ( Figure 3C ).
Dendritic spine density of both apical and basal dendrites was reduced in Sez6 cKO neurons in Figure 5D ). Our findings revealed no obvious pre-synaptic alteration, implying that the LTP changes should be caused mainly by post-synaptic alterations.
Discussion
As the most common form of senile dementia, AD is a great burden for patients, their families, society and Presently, a lot of research effort is focused on BACE1, the rate-limiting enzyme in the amyloidogenic cascade (36) . BACE1 activity can be blocked by small molecule drugs (26; 37; 38) . Further promising data are coming from mouse models: Bace1 -/-mice are viable and fertile (23) and when crossed with AD mouse models reduction of disease pathology is observed (39) (40) (41) . However, the disappointing outcome of γ-secretase inhibitor trials calls for caution, which is due to on-target interference with Notch and other signaling pathways (42; 43) . It is therefore crucial to understand the physiological role of BACE1 and its substrates. This is underpinned by our recent in vivo study in which we reported that treatment with highdose BACE1 inhibitor affects structural and functional synaptic plasticity in mice (10) .
In our present study, we hypothesized that BACE1-inhibition-induced structural and functional synaptic alterations are caused by disruption of the Sez6 function. This hypothesis is based on the fact that Sez6 is predominantly and initially processed by BACE1 (15; 16) and that Sez6 -/-mice display certain similar deficits comparable to BACE1 inhibited (10; 20) and BACE1 knockout mice (44) . These deficits include reduced dendritic spine density, poor motor coordination, and diminished performance in hippocampaldependent behavioral tests (17) . We targeted BACE1 with NB-360, a novel inhibitor developed by Novartis (26) , which almost completely blocked BACE1 activity in our study, similar to the previously reported high efficacy of BACE1 inhibitors SCH1682496 and LY2811376 (10; 37; 45). To better understand the role of Sez6 in BACE1-inhibition induced effects, we used chronic in vivo two-photon microscopy and electrophysiological field recordings in NB-360 treated WT and Sez6 knockout mice. Our main findings strongly support the role of Sez6 in the BACE1-inhibition induced synaptic alteration.
Treatment with NB-360 inhibitor did not induce spine density reduction in constitutive knockout (Sez6 -/-) mice. In contrast, in control WT mice, we could observe a reduction to the similar extent as in our previous study where we administrated two other BACE1 inhibitors. Since three structurally different BACE1
inhibitors (NB-360, SCH1682496 and LY2811376) influenced spine plasticity in similar manner. In addition these inhibitor (SCH1682496 and LY2811376) effects were absent in treated Bace1 -/-mice (10),
we are convinced that off-target effects are rather unlikely (46) . One possibility is that observed lack of NB-360 effect in Sez6 -/-mice is masked by developmental deficits. Namely, it is known that Sez6 -/-mice have reduced spine density and altered neurite branching during development (17 :SlickV mice, dendritic spine density was lower indicating that Sez6 is not only critical for neuronal development, but also important for maintaining the normal dendritic spine density in adult mice.
However, the spine density reduction in Sez6 cKO/cKO neurons is smaller than the reduction seen in Sez6 -/-, which may be attributed to a general increase of dendritic spine stability in adulthood (47; 48). Importantly, conditional knockout of Sez6 in a subset of neurons also prevented NB-360 induced synaptic changes, further confirming critical role of Sez6 in dendritic spine plasticity.
Another advantage of the conditional knockout model is that only a small subset of eYFP/CreER T2 positive Sez6 cKO/cKO neurons is exposed to a relatively normal extracellular environment (Figure 6 ), i.e. the majority of neighboring neurons are not affected (27) . NB-360 treatment should decrease sSez6 (soluble Sez6) production in these unaffected neurons lowering the extracellular concentration of the sSez6. Interestingly, according to our chronic in vivo imaging, such altered environment did not change dendritic spine density in Sez6 cKO/cKO neurons. Taken together, these data suggest that flSez6 (full length) or Sez6-CTF (C-terminal fragment), which are absent from a subset of neurons after Sez6 deletion, might be important for regulation of dendritic spine density ( Figure 6 ). However, based on our measurements, we cannot exclude the possibility that soluble Sez6 may be still involved in this process.
Can NB-360 treatment cause functional impairments in WT mice, and are these impairments mediated by Sez6 protein? To gain insight into potential electrophysiological alterations, we performed hippocampal field recordings using acute brain slices from age-matched WT and Sez6 -/-mice treated for 21 days with
NB-360. Sez6 -/-mice show attenuated Schaffer collateral-CA1 LTP, which is consistent with previous data
showing defects in hippocampus-dependent memory (17) . Chronic BACE1 inhibition does not attenuate the weakened LTP any further, indicating that Sez6 is involved in BACE1-inhibition-induced reduction in functional synaptic plasticity observed in WT mice. Since hippocampal dendrites undergo spinogenesis after LTP induction (49; 50), the observed LTP attenuation in Sez6 -/-mice may be a consequence of impaired structural dendritic spine plasticity. This is consistent with the overall decrease in spine density that we detected. In our experiments, LTP is induced by high frequency stimulation. It was previously shown that Sez6 mRNA levels are increased after strong neuronal activity (14) . This increase in Sez6 expression is dependent on NMDA-receptor activation (51) , which may imply that Sez6 is functionally involved in LTP maintenance.
Due to Sez6 predominately locates at somatodendritic compartment (17), we hypothesized that Sez6 is mainly involved in post-synaptic transmission. Sez6 knockout did not affect paired-pulsed facilitation in our study supporting a post-synaptic role for Sez6. Surprisingly, pre-synaptic deficits were also not observed in NB-360 treated WT mice, although BACE1 accumulates in pre-synaptic terminals (52; 53) and Bace1 -/-mouse neurons display a pre-synaptic dysfunction at the mossy fiber terminals (54; 55) . This may be due to differences in the developmental trajectory of Bace1 knockout-induced phenotypes compared to BACE1
inhibitor treated adult mice. In addition, different results might have been obtained by studying different brain regions (Stratum radiatum of CA1 in our study vs mossy fiber terminals in another study (54) ).
What other BACE1 substrates may be involved in the functional deficits we observed? Interestingly, a recent studies reported that BACE1 inhibition increases a moderate increase of sAPPα (26) and Aη-α, a novel proteolytic fragment of APP (56) . It was shown that sAPPα and Aη-α have opposite effects on hippocampal LTP. Overexpression of sAPPα rescued LTP reduction in an AD mouse model (57), whereas application of Aη-α supplemented media attenuates hippocampal LTP in WT mice (56) . However, we did not observe the LTP alteration in slice from NB-360 treated Sez6 -/-mice. Since sAPPα and Aη-α are both present in our acute slice preparation, the opposing effects of these peptides could cancel each other.
Alternatively, since both peptides are extracellular soluble proteins they might be washed out during the incubation period.
Finally, a profound understanding of BACE1 mechanisms of action and physiological role of BACE1 substrates has additional important implications for clinical studies and potential therapies. A recent report described an endosomally targeted sterol-linked BACE1 inhibitor, which inhibits Aβ production without affecting β-cleavage of NRG1 and L1 (58) . Both APP and Sez6 contain NPxY motifs for the endocytosis in their intracellular domains (59; 60) indicating that Sez6 also undergoes endocytosis (19) similar to APP (61) . Therefore, this sterol-linked BACE1 inhibitor may also interfere with Sez6 processing. This notion is important because then Sez6 might serve as a useful indicator in preclinical testing of novel BACE1
inhibitors. By monitoring levels of Sez6 and its proteolytic fragments, it would be possible to gain insight in BACE1 inhibitors ability to reduce Aβ levels preferentially, while preserving physiological functions of BACE1 substrates.
In conclusion, our findings confirm the disruptive effects of BACE1 inhibition on synaptic function and plasticity in WT mice. We also showed that Sez6 is involved in dendritic spine dynamics and post-synaptic functions in mice. Finally, we showed that impaired processing of Sez6 is one of the main reasons for the observed BACE1-inhibition-induced synaptic alterations in mice. As a reduction in dendritic spine density is linked to cognitive decline, the clinical hallmark of AD (11), all treatments should be designed to avoid potential synaptic side effects. Fortunately, this BACE1-inhibition-induced synaptic interference can be potentially prevented by lowering the inhibitor dosage (10; 46), supporting BACE1 inhibition as a valid therapeutic approach. It is therefore important to study potential BACE1-inhibition-induced synaptic alterations and the role of Sez6 in healthy humans and AD patients. Finally, soluble Sez6 is detectable in CSF (62; 63) suggesting it might be considered as a biomarker to establish optimal dosage of BACE1
inhibitors to avoid potential treatment-induced synaptic impairments. Norm. fEPSP Slope (%) Figure 5 Zhu et al., Figure 6 
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